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Samara Naim and Thomas Kaufmann*
Institute of Pharmacology, University of Bern, Bern, Switzerland
BCL-2–related ovarian killer (BOK) is—despite its identification over 20 years ago—
an incompletely understood member of the BCL-2 family. BCL-2 family proteins are
best known for their critical role in the regulation of mitochondrial outer membrane
permeabilization during the intrinsic apoptotic pathway. Based on sequence and
structural similarities to BAX and BAK, BOK is grouped with these “killers” within the
effector subgroup of the family. However, the mechanism of how exactly BOK exerts
apoptosis is not clear and controversially discussed. Furthermore, and in accordance
with reports on several other BCL-2 family members, BOK seems to be involved in
the regulation of a variety of other, “apoptosis-independent” cellular functions, including
the unfolded protein response, cellular proliferation, metabolism, and autophagy. Of
note, compared with other proapoptotic BCL-2 family members, BOK levels are
often reduced in cancer by various means, and there is increasing evidence for BOK
modulating tumorigenesis. In this review, we summarize and discuss apoptotic- and
non–apoptotic-related functions of BOK, its regulation as well as its physiological and
pathophysiological roles.
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INTRODUCTION: THE BCL-2 PROTEIN FAMILY IN APOPTOSIS
Apoptosis, the first described and probably best understood form of programed cell death, is a
physiological process that actively leads to the death of a cell. Apoptosis is critical for the removal
of old, unwanted or critically damaged cells, both during development and for the maintenance
of cellular homeostasis in adult multicellular organisms. Its regulation reaches the complexity of
cell growth and cell proliferation, and a fine-tuned and self-regulatory balance between cell growth
and cell death guarantees the healthy state of individual organisms (Singh et al., 2019). Cellular
turnover in adult humans is estimated to be around 1 million per second (Reed, 2006). Given
the massive number of cells constantly dying in our bodies, it is not surprising that nature has
ensured a highly efficient, fast, and safe removal process of dying cells. However, there is a strong
connection between the imbalance in apoptosis regulation and various pathophysiologies (Favaloro
et al., 2012). Many cancer cells, for example, increase their prosurvival activity during the process
of malignant transformation or in the course of radiotherapeutic/chemotherapeutic intervention,
contributing to the development of resistance against apoptotic stimuli. One commonly observed
way to achieve this is through upregulation of antiapoptotic BCL-2 family members, such as
BCL-2, BCL-XL, or MCL-1 (Campbell and Tait, 2018). To overcome such apoptosis resistance of
cancer cells, great interest in developing specific inhibitors of antiapoptotic BCL-2 proteins, so-
called BH3 mimetics, has arisen over the past years, with a first compound [the BCL-2–specific
inhibitor venetoclax (Venclexta)] approved by the US Food and Drug and Administration for
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chronic lymphocytic leukemia and acute myeloid leukemia
(Montero and Letai, 2018; Timucin et al., 2019). On the other
hand, excessive apoptosis is described in neurodegenerative
diseases such as Alzheimer and Huntington disease (Mattson,
2000; Ghavami et al., 2014).
Central to apoptosis induction are cysteine aspartate–specific
proteases, called caspases. Caspases form an evolutionary
conserved family of cysteine proteases involved in cell death
(apoptotic caspases), as well as inflammatory responses
(inflammatory caspases) (Zheng et al., 1999; Van Opdenbosch
and Lamkanfi, 2019). Apoptotic caspases can be subdivided
into initiator (caspases-8, -9, and -10) and effector caspases
(caspases-3, -6, and -7) (Van Opdenbosch and Lamkanfi,
2019). Caspases are mainly abundant in their inactive state as
procaspases (Mcilwain et al., 2013). Once autoactivated following
intrinsic or extrinsic initiation of apoptosis, initiator caspases
activate effector caspases through proteolytic cleavage (Shi,
2004). Activated effector caspases then cleave cellular substrates
leading to cell death (Julien and Wells, 2017).
Members of the BCL-2 family are central regulators of
the so-called intrinsic, or mitochondrial, apoptotic pathway,
a pathway that can be activated in possibly all cell types in
response to a plethora of intrinsic stress (“apoptotic”) stimuli.
These include DNA damaging insults, oxidative stress, aberrant
calcium fluxes, endoplasmic reticulum (ER) stress, nutrient
deprivation, or infection by pathogens, among others (Lopez
and Tait, 2015). Once activated, the intrinsic apoptotic pathway
results in the BCL-2 family regulated discrete permeabilization of
the mitochondrial outer membrane (MOMP), with subsequent
release of many proteins from the mitochondrial intermembrane
space into the cytoplasm. Among the latter are apoptogenic
proteins (such as cytochrome c or SMAC/DIABLO), which
are needed for—or facilitate—the downstream activation of
apoptotic caspases (Lopez and Tait, 2015).
The members of the BCL-2 family are small globular proteins
that contain up to four rather loosely conserved Bcl-2 homology
(BH) domains, BH1–BH4. All family members contain the
hydrophobic BH3 domain, which is important for protein–
protein interaction between the various BCL-2 proteins, and
most members contain a C-terminal α-helical transmembrane
domain (TMD) that serves to tail-anchor the protein to
intracellular membranes (Schinzel et al., 2004; Wilfling et al.,
2012). Based on structural and functional homologies, the family
is classified into three subgroups: the antiapoptotic proteins
(BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1/BCL-2A1, and BCL-
B), the proapoptotic BH3-only proteins (BAD, BID, BIK, BIM,
BMF, HRK, NOXA, PUMA), and the proapoptotic effector
proteins BAX, BAK, and BCL-2–related ovarian killer (BOK)
(Adams and Cory, 2018).
The interaction of the BCL-2 proteins depends on the
abundance, the attraction, and the affinity of the proteins.
The affinity between different proteins on its part results from
conformational changes of the proteins (Kale et al., 2018). There
are three main types of interaction: (1) binding of the BH3
domain of so-called “activator” BH3-only proteins (such as
BIM or BID) to the BH3-binding groove of the effectors BAX
and/or BAK, leading to their direct activation; (2) binding of
the BH3-binding groove of antiapoptotic proteins to the BH3
domain of BAX/BAK or activator BH3-only proteins, leading to
their sequestration; (3) binding of the BH3 domain of so-called
“sensitizer” BH3-only proteins (such as BAD or NOXA) to the
BH3-binding groove of antiapoptotic proteins, leading to their
inactivation (Kale et al., 2018).
The ultimate goal of the early initiation phase of intrinsic
apoptosis is MOMP. Whether or not MOMP occurs depends
on the ratio between proapoptotic and antiapoptotic proteins,
or more precisely, on their activation status and the interactions
between them (Kale et al., 2018). Equally important seems the
composition of the lipid bilayer of the mitochondrial outer
membrane (MOM), where most of the previously described
interactions take place and which has an active role in
facilitating structural changes of the BCL-2 proteins, resulting
in affinity changes and consequently alterations of interactions
(Kale et al., 2018).
Once activated, the effector proteins BAX and BAK
oligomerize to form pores leading to MOMP (Cosentino
and Garcia-Saez, 2017), a process described as point of no return
during the initiation of intrinsic apoptosis. While BAK is already
located at the MOM, BAX translocates from the cytosol to the
mitochondrial membrane upon activation (Wolter et al., 1997;
Todt et al., 2015).
Whereas regulation of the intrinsic apoptotic pathway,
specifically MOMP, is the best understood role of BCL-2
family members, it is important to mention that for most—
if not all—members, other, distinct non-apoptotic roles have
been described. These range from modulating mitochondrial
shape and metabolism, calcium flux, the unfolded protein
response (UPR), DNA damage response, glucose and lipid
metabolism to cellular proliferation and autophagy [reviewed in
(Gross and Katz, 2017)].
A SHORT HISTORY OF BOK
BOK was first discovered in 1997 by Hsu et al. (1997) in a
yeast two-hybrid screen of a rat ovarian fusion library using
MCL-1 as a bait and by Inohara et al. (1998) by sequence
homology prediction screening, naming it “matador” (MTD),
meaning killer in Spanish. Hsu et al. (1997) initially described
BOK as highly and restrictedly expressed in rat ovaries, testis
and uterus, hence the name “Bcl-2–related ovarian killer.” Within
the first years after its discovery, only a few articles on BOK
were published. Besides classifying it as a proapoptotic BCL-
2 protein based on transient overexpression experiments and
describing first interaction partners (MCL-1, BHRF1, and BFL-
1, but not BCL-2, BCL-XL, or BCL-W) (Hsu et al., 1997),
sequence analyses revealed BOK as an evolutionarily highly
conserved BCL-2 member (Zhang et al., 2000). Not only was
it reported to be important for apoptosis regulation in normal
B-cell development in chicken (Brown et al., 2004) but also for the
increased trophoblast cell death found in preeclampsia, regulated
by the MCL-1/MTD (BOK) rheostat (Soleymanlou et al., 2005;
Soleymanlou et al., 2007). The interest in BOK rapidly increased
in 2010 upon the discovery that the locus containing the BOK
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 September 2020 | Volume 8 | Article 574338
fcell-08-574338 September 11, 2020 Time: 18:24 # 3
Naim and Kaufmann The BCL-2 Family Member BOK
gene is frequently deleted across human cancers, thus indicating
a possible tumor suppressor role for BOK (Beroukhim et al.,
2010) as well as the characterization of the first Bok-deficient
mouse model in 2012 (Ke et al., 2012). This latter study showed
that the expression of BOK is, in contrast to earlier assumptions
(Hsu et al., 1997), not restricted to reproductive organs but rather
widely distributed across tissues, in which it is detectable both
at mRNA and protein levels (Ke et al., 2012). Because of its
proapoptotic potential and its considerable amino acid sequence
homologies with BAX and BAK, BOK was clustered in the
effector (“killer”) subgroup of the BCL-2 family of proteins (Hsu
et al., 1997). Until recently, there was no structural information
available on BOK. The structural similarities between BOK
and BAX/BAK were substantiated in 2018 by two independent
studies using X-ray crystallography on chicken BOK and NMR
spectroscopy on human BOK, respectively (Ke et al., 2018;
Moldoveanu and Zheng, 2018; Zheng et al., 2018). However,
as discussed in more detail below, there are several important
differences that distinguish BOK properties and functions from
those of BAX or BAK. More than 20 years after its discovery,
the role of BOK in apoptosis is not entirely understood and
to some extent controversially discussed (Yakovlev et al., 2004;
Jaaskelainen et al., 2010; Carpio et al., 2015; D’Orsi et al.,
2016; Einsele-Scholz et al., 2016; Llambi et al., 2016; Fernandez-
Marrero et al., 2017; Moldoveanu and Zheng, 2018; Schulman
et al., 2019). There is increasing evidence supporting roles of BOK
in cellular functions other than cell death regulation, namely,
uridine metabolism and cellular proliferation (Ray et al., 2010;
Moravcikova et al., 2017; Rabachini et al., 2018; Srivastava et al.,
2019), autophagy (Kalkat et al., 2013), mitochondrial physiology
(D’Orsi et al., 2017; Ausman et al., 2018; Schulman et al., 2019),
ER homeostasis, and modulation of the UPR (Echeverry et al.,
2013; Carpio et al., 2015; Schulman et al., 2016; Moravcikova
et al., 2017; Kang et al., 2019). Thus, there are many open
questions remaining to fully understand the different roles and
functions of this protein.
BOK GENE TARGETING IN MICE
The first Bok−/− mouse was published in 2012 by Ke et al., using
homologous recombination in C57BL/6-derived embryonic stem
cells targeting half of exon 1 and exon 2 of Bok (with exon 2
containing the ATG start site) (Ke et al., 2012). BOK knockout
mice did not show an overt phenotype and were produced at
the expected Mendelian frequency (Table 1; Ke et al., 2012).
Investigated organs of Bok−/− mice appeared normal, and there
was no difference in hematopoietic cell subset composition (Ke
et al., 2012). An important message of this study was that
BOK is widely expressed in mouse tissues and readily detectable
at the protein level in most tissues analyzed. Expression in
the bone marrow, however, was shown to be low. Among the
hematopoietic subsets, BOK expression was highest in myeloid
cells but very low in lymphoid cells. These expression profiles
may explain the finding that loss of BOK did not accelerate
lymphoma development in Eµ-myc transgenic mice (Ke et al.,
2012). Along the same line, Bok-deficient lymphoid and myeloid
cells were found to respond normally to the classic apoptotic
stimuli etoposide, dexamethasone, FasL, or the BH3 mimetic
ABT-737 (Ke et al., 2012).
Lack of a spontaneous phenotype was confirmed in two
independently derived Bok-deficient mouse models (Carpio et al.,
2015; Llambi et al., 2016). This finding was no great surprise, also
given that neither BAX nor BAK single knockout mice display
major phenotypes, with the exception of testicular atrophy
and infertility seen in Bax−/− males (Knudson et al., 1995;
Lindsten et al., 2000).
While loss of either BAK or BAX alone is compatible with the
development of mice, Bax−/−Bak−/− double-knockout (DKO)
mice are obtained at less than 10% of the expected Mendelian
frequency, and only few survive into adulthood (Lindsten et al.,
2000; Mason et al., 2013). Those surviving mice develop severe
neurological and hematopoietic abnormalities, splenomegaly,
and lymphadenopathy (Lindsten et al., 2000). On the other
hand, combined gene knockouts of Bok and Bax, or Bok and
Bak, respectively, did not worsen the phenotype of Bak−/− or
Bax−/− single knockout mice, except for an increased oocyte
count in Bax−/−Bok−/− DKO females (Ke et al., 2013). Mice
lacking BAX, BAK, and BOK [triple-knockout (TKO)] in the
hematopoietic system showed a slightly more severe phenotype
compared to respective Bax−/−Bak−/− DKO controls, including
increased levels of autoantibodies and leukocyte infiltration in
several organs (Ke et al., 2015). These data were an early
indication that BOK may have redundant functions with BAX
and BAK. The proof that BOK indeed has overlapping functions
with BAX and BAK also beyond the hematopoietic compartment
came with the generation of full-body Bax−/−Bak−/−Bok−/−
TKO mice in 2018 by Ke et al. (2018). This article showed
that TKO mice develop more severe defects and die earlier
compared with Bax−/−Bak−/− DKO mice, with 99% developing
lethal abnormalities. With developmental defects starting from
E11.5, TKO pups at E18.5 showed, among others, multiple
midline defects and aortic arch defects, as well as abnormal tissue
growth in multiple organs, all of which were thought to be a
consequence of inactivated intrinsic apoptosis (Ke et al., 2018).
Besides providing the current best evidence for a physiologically
relevant role of BOK in apoptosis and embryogenesis, this study
also demonstrated that multiple organs develop more or less
normally in TKO mice and that a small proportion (1%) of
TKO mice even survives into adulthood, indicating that intrinsic
apoptosis is not strictly required for the development of mice
(Ke et al., 2018).
INTERACTION PARTNERS AND
SUBCELLULAR LOCALIZATION OF BOK
So far, only a few BOK interacting partners have been described
(Figure 1). Using yeast two-hybrid screens, BOK was found
to interact with some selected antiapoptotic members of the
BCL-2 family, i.e., MCL-1, BFL-1/BCL-2A1, and the Epstein-
Barr virus BCL-2 homolog BHRF1, but neither with BCL-2,
BCL-XL, or BCL-W, nor with BAX or BAK (Hsu et al., 1997;
Srivastava et al., 2019). Using co-immunoprecipitation assays of
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TABLE 1 | Bok-deficient mouse models.
Model Targeting strategy/comments Characteristics References
Bok−/− • Homologous recombination in C57BL/6 derived ES
cells; C57BL/6J genetic background
• Deletion of half of exon 1 and exon 2
• No overt phenotype
• Reproduction at expected Mendelian frequency
Ke et al., 2012
Bok−/− • Homologous recombination in 129-derived ES cells;
backcrossed to C57BL/6 genetic background
• Deletion of exons 2 and 3
• Normal development Carpio et al., 2015
Bok−/− • Homologous recombination in 129/SvEv derived ES
cells; backcrossed to C57BL/6N genetic background
• Deletion of exons 2–5
• No overt phenotype Llambi et al., 2016
Eµ-myc/Bok−/− • Crossing Eµ-myc transgenic mice with full-body
Bok−/− mice (Ke et al., 2012)
• No acceleration of lymphoma development and no
impact on disease severity compared to Eµ-myc
transgenic mice
Ke et al., 2012
Nup98-HoxD13
(NHD13)/Bok−/−
• Crossing NHD13 transgenic mice with full-body
Bok−/− mice (Carpio et al., 2015)
• Acute myeloid leukemia development in 36.7% of
mice
• Development of progressive anemia: lower
hemoglobin, lower mean cell hemoglobin
concentration, higher mean cell volume
Kang et al., 2019
Bok−/−Bak−/− DKO • Crossing Bak−/− mice with Bok−/− mice • No noticeable defects compared to BAK−/− single
knockout
Ke et al., 2013
Bok−/−Bax−/− DKO • Crossing Bax−/− mice with Bok−/− mice • Increased ovarian follicle numbers at 1 year of age Ke et al., 2013
Bok−/−Bax−/−Bak−/−
TKO in the hematopoietic
system
• Bone marrow chimeras obtained by injection of TKO
fetal liver cells (FLC, E14) into lethally irradiated
wild-type recipients
• Slightly more severe phenotype compared to mice
reconstituted with FLCs of Bax−/−Bak−/− DKO mice
• Increased numbers of leukocytes in the periphery, as
well as in several organs
• Lymphocytic infiltration in multiple organs and
organ-specific autoantibodies
Ke et al., 2015
Bok−/−Bax−/−Bak−/−
full-body TKO
• Crossing Bok−/− (Ke et al., 2012), Bax−/− (Knudson
et al., 1995) and Bak−/− (Lindsten et al., 2000) mice;
C57BL/6J genetic background
• 1% of mice survive into adulthood
• Developmental defects at E11.5
• Multiple midline defects at E18.5
• Pups develop abnormal tissue growth in multiple
locations
Ke et al., 2018
overexpressed proteins, Echeverry et al. reported failure of BOK
to interact with any tested BCL-2 family member (BCL-2, BCL-
XL, MCL-1, BAX, BAK), with the exception of BOK itself, an
interaction that is dependent on critical amino acids within the
BH3 domain (Echeverry et al., 2013). However, there currently
are no convincing data published that BOK forms dimers or
higher homo-oligomers or hetero-oligomers. Moreover, both
yeast two-hybrid screens and co-immunoprecipitation assays are
error-prone; thus, more reliable assays are needed to clarify
the interactions of BOK with other family members. Like most
BCL-2 proteins, BOK contains a C-terminal TMD that serves
as a tail-anchor domain for the posttranslational insertion at
the cytoplasmic side of intracellular membranes (Hsu et al.,
1997; Schinzel et al., 2004). Tail anchors are both necessary and
sufficient to target a protein to the ER, the MOM, or to other
intracellular membranes, whereas they are not always specific for
a single compartment with known examples of dual targeting of
ER and MOM (Borgese and Fasana, 2011). Echeverry et al. (2013)
have demonstrated that the TMD of BOK has a high affinity for
the ER, Golgi, and associated membranes, into which it integrally
inserts. However, whereas the majority of BOK is located at the
ER, BOK can also be found at the mitochondria (Ray et al., 2010;
Echeverry et al., 2013; Einsele-Scholz et al., 2016; Ausman et al.,
2018) and has further been reported to localize to the nucleus,
where its role is still rather enigmatic (Bartholomeusz et al., 2006;
Echeverry et al., 2013). In contrast to most other multi–BH-
domain BCL-2 proteins, which contain a classic hydrophobic
TMD, the TMD of BOK is peculiar in that it comprises two
positively charged amino acids (aa) in its center (R200 and K203
in mouse BOK) (Lindsay et al., 2011). The functions of these
polar aa are not clear, but may affect the topology of the BOK
TMD and its membrane insertion; on the other hand, it may
also be speculated that these polar aa mediate intramembranous
homodimerization or heterodimerization with polar TMDs of
interaction partners.
BOK’s dominant localization at the ER is an important
distinction from BAX or BAK and is much in line with
increasing evidence for a role of BOK in the modulation of ER
stress responses (see below). This is also strongly supported by
the direct interaction of BOK with inositol 1,4,5-trisphosphate
receptors (IP3R), in particular with IP3R1 and IP3R2, as
identified by the Wojcikiewicz laboratory (Schulman et al., 2013,
2016). This interaction was shown to be strong and constitutive
and mediated by the N-terminal BH4 domain of BOK binding to
a region within the IP3R coupling domain, a region to which no
other BCL-2 family member has been reported to bind. Through
this interaction, BOK protects IP3R from caspase-3–mediated
degradation during apoptosis (Schulman et al., 2013). However,
no direct effect of BOK in altering Ca2+ mobilization by IP3Rs
was observed (Schulman et al., 2013). Nevertheless, a role for
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FIGURE 1 | Interaction partners of BOK. Only few BOK interacting partners have been described so far. Using yeast two-hybrid screens, BOK was found to interact
with MCL-1. This interaction has been proposed to promote autophagy, as BOK binding to MCL-1 frees MCL-1–bound Beclin-1, which in turn initiates the
autophagy machinery. Moreover, BOK is constitutively bound to IP3Rs (IP3R1 and IP3R2) at the ER via its BH4 domain. IP3Rs may act as a regulatory sink for BOK
to keep the levels of unbound (“free”) BOK low. Furthermore, co-immunoprecipitation experiments indicated that BOK may interact with itself in a BH3
domain–dependent manner. Whether BOK truly forms dimers or homo-oligomers and whether this oligomerization induces MOMP need to be further investigated.
Recently, BOK was found to interact with and increase the activity of the enzyme UMPS via its BH3 domain. UMPS catalyzes the last two steps of the de novo
synthesis of UMP and is central for metabolizing the chemotherapeutic drug 5-FU into its active metabolites. As a result, cells lacking BOK have a defect in uridine
metabolism, leading to decreased cellular proliferation compared to WT controls. On the other hand, Bok-/- cells are resistant toward 5-FU treatment. Losing BOK
seems to confer a selective advantage to CRC cells, and consequently, BOK expression levels are suggested to be useful as a prognostic marker in CRC and as a
predictive marker for the efficacy of 5-FU treatment in CRC. While there is increasing evidence for a UPR-modulating role for BOK, the exact mechanism and
possible interaction partners for UPR modulation and the ER stress response are still unknown.
BOK in maintaining Ca2+ homeostasis in response to excitotoxic
stimulation has been described in neurons, and this phenotype
was linked to a decreased protein stability of MCL-1 observed in
the absence of BOK (D’Orsi et al., 2016). Importantly, Schulman
et al. (2016) showed that BOK is stabilized when bound to IP3R
and that its proapoptotic activity is thereby likely limited, whereas
unbound (“free”) BOK is rapidly degraded by the ubiquitin
proteasome pathway. In consideration of the potent proapoptotic
activity of BOK reported by Llambi et al. (2016), it can be argued
that IP3Rs may act as a regulatory sink for BOK to keep the levels
of unbound (“free”) BOK low (Figure 2). Furthermore, Schulman
et al. (2016) also identified an alternative start site for BOK at
Met15, resulting in a shorter protein that should not be mistaken
for BOK’s shorter isoform, BOK-S. Regulation and functional
relevance of the resulting N-terminally truncated BOK protein is
currently unknown and needs further investigation.
Recently, BOK was identified to interact with uridine
monophosphate synthetase (UMPS) (Figure 1; Srivastava et al.,
2019). UMPS, which in higher eukaryotes is a bifunctional
enzyme consisting of the orotate phosphoribosyltransferase
(OPRTase) and orotidine decarboxylase (ODCase) domains, is a
central enzyme catalyzing the final steps in the de novo synthesis
of orotate to uridine monophosphate (UMP) (Qumsiyeh et al.,
1989). BOK binds to the ODCase domain at its dimer interface in
a BH3-dependent manner (Srivastava et al., 2019). Intriguingly,
it was found that, through this interaction, BOK increases the
enzymatic activity of UMPS approximately threefold (Srivastava
et al., 2019). As a consequence, cells lacking BOK have a defect
in uridine metabolism, which affects crucial metabolic pathways
including pyrimidine nucleotide synthesis, resulting in decreased
cellular proliferation of Bok−/− cells compared with WT controls
(Rabachini et al., 2018; Srivastava et al., 2019). On the other
hand, loss of BOK confers resistance to 5-fluorouracil (5-FU)–
induced apoptosis, as UMPS catalyzes the biotransformation of
5-FU into its active downstream metabolites. As discussed below,
there are important implications of these findings for cancer
biology, as colorectal cancer (CRC) cells may have a selective
advantage from losing BOK expression (Srivastava et al., 2019).
The study by Srivastava et al. provides the first link between
BOK and uridine metabolism. Along that line, a connection
from BOK to mitochondrial bioenergetics, fusion/fission and
morphology has recently been reported also, further supporting
apoptosis-independent roles of BOK (D’Orsi et al., 2016; Ausman
et al., 2018; Schulman et al., 2019). Taken together, there is solid
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FIGURE 2 | Intracellular localization and cellular functions of BOK. BOK was described to exert various cellular functions at steady state and upon stress exposure,
probably dependent on its various subcellular localizations. At steady state, the majority of BOK is bound to the ER, Golgi, and associated membranes. However, it
can also be found within the nucleus, where its role is unclear, as well as on the MOM and ER-mitochondrial contact sites. ER-localized BOK is bound to IP3R and
stabilizes the latter from caspase-3–mediated cleavage. IP3R-bound BOK, on the other hand, is stabilized from proteasomal turnover, as unbound, “free” BOK is
ubiquitinated and degraded by the ERAD pathway. IP3R-bound BOK may thus not be available for mitochondrial apoptosis induction. No direct effect of BOK in
altering Ca2+ mobilization by IP3Rs has been observed so far. Recently, BOK was found to be important for mitochondrial fission and morphology and thus to affect
mitochondrial membrane potential. BOK has furthermore been described to exert a BAX-like killing function. Disturbance of components of the ERAD pathway
thereby results in the stabilization of “free” BOK protein, which then directly induces MOMP and apoptosis in a BAX-like manner, independently of other BCL-2 family
members. Under certain stress conditions, e.g., under hypoxia, BOK is upregulated and translocates from the nucleus into the cytoplasm and to mitochondrial
membranes by a still unknown mechanism, where it may induce apoptosis. Increasing evidence points toward a UPR-modulating function by BOK, following ER
stress, by a yet unknown mechanism. In that respect, BOK was described to regulate the PERK > ATF4 arm along with CHOP, which induces the BH3-only protein
BIM (and PUMA). BIM directly activates BAX/BAK, leading to MOMP and subsequent apoptosis, suggesting an apoptosis-inducing role of BOK upstream of MOMP
in that context.
evidence published for the interaction of BOK with IP3R1/-2,
as well as with UMPS. Regarding the BCL-2 proteins, the best
evidence for interaction is with MCL-1 (Figure 1).
VARIOUS MODELS OF BOK-INDUCED
APOPTOSIS
The role and exact molecular function of BOK in apoptosis is
still not fully understood. Since its discovery, BOK has been
grouped together with BAX and BAK as “killer”; however,
whether BOK induces MOMP in the absence of BAX or BAK and
how relevant BOK-induced apoptosis is for (patho)physiology
are currently controversially discussed. Earlier reports provided
evidence that BOK induces intrinsic apoptosis, but these studies
were restricted to transient overexpression and were performed
in BAX/BAK-proficient cell lines (Hsu et al., 1997; Yakovlev
et al., 2004; Rodriguez et al., 2006). Whereas it seems to be
clear that high levels of BOK can induce apoptosis, two studies
reported that cell death induced by overexpressed BOK is much
reduced in Bax−/−Bak−/− DKO cells (SV40-immortalized
MEF, Hoxb8-immortalized growth factor–dependent myeloid
progenitors) compared to WT controls (Echeverry et al., 2013;
Carpio et al., 2015). These data implied that BOK may act
upstream of BAX/BAK-mediated MOMP, which is in line with
its predominant subcellular localization at the ER and its role
in modulating ER stress responses (Echeverry et al., 2013;
Carpio et al., 2015; Llambi et al., 2016). On the other hand,
several studies reported that increased BOK levels are able to
kill Bax−/−Bak−/− DKO cells (HCT116, SV40 MEF) and to
induce MOMP in the absence of BAX and BAK, implying a
true BAX-like effector function of BOK at the MOM (Figure 2;
Einsele-Scholz et al., 2016; Llambi et al., 2016; Zheng et al.,
2018). While these latter reports are in strong support for BOK-
induced MOMP, biophysical evidence for an oligomerization of
BOK and direct pore formation in the MOM is currently missing.
Of note, while recombinant forms of BOK readily permeabilized
artificial membrane vesicles, in particular when their composition
mimicked the MOM, it failed to do so on isolated mitochondria
lacking BAX and BAK, even in the presence of the activator BH3-
only protein tBID (Fernandez-Marrero et al., 2017). A possible
alternative explanation was put forward by Llambi et al. (2016)
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FIGURE 3 | Transcriptional and posttranslational regulation of BOK. The expression of BOK is regulated at transcriptional, epigenetic, translational, and
posttranslational levels. In a variety of human cancers, the genomic region containing the BOK locus on chromosome 2 is deleted. Within its promoter region, BOK
contains HREs, as well as a conserved E2F1-binding site. Upon binding by hypoxia-inducible factors (HIFs) and the cell cycle–regulating transcription factor E2F1,
respectively, BOK transcription is induced. On the other hand, by means of promoter methylation, BOK can be epigenetically silenced. BOK comprises five exons.
Alternative splicing leads to the development of the poorly understood BOK isoforms BOK-S and BOK-P. The expression of BOK is furthermore regulated at the level
of mRNA stability. The miRNA miR-296-5p has been shown to bind to the 3’ UTR of BOK mRNA, leading to its degradation. Moreover, strongly destabilizing
(AU/U)–rich elements (one ARE site in mouse Bok mRNA, two URE sites in human BOK mRNA) were described in the 3’ UTR of BOK. Tripartite motif containing 28
(TRIM28) was identified to bind to this region, leading to destabilization and subsequent degradation of human BOK mRNA. Once translated, BOK is mainly localized
at ER membranes, where it is bound to IP3Rs. Unbound BOK is quickly turned over by the ERAD pathway, resulting in ubiquitin-proteasomal degradation.
and Zheng et al. (2018), who proposed a unique mechanism
for BOK-induced MOMP, which is independent of interaction
with tBID or other BCL-2 family members. Interestingly, this
mechanism relies on an intrinsic instability of BOK (hydrophobic
groove and helix α1), which results in its spontaneous association
with mitochondria and MOMP, independent of the activation
by BH3 ligands of other BCL-2 family members. Because of
this model, BOK is expected to be a very potent inducer of
MOMP and apoptosis, and thus, BOK levels need to be tightly
controlled. One way to control BOK levels is through ER-
associated degradation (ERAD), with a high turnover of BOK
via ubiquitination and proteasomal degradation (Figures 2, 3;
Llambi et al., 2016). However, several reports have shown that
many cell types or tissues can tolerate high levels of BOK protein
(Ke et al., 2012; Moravcikova et al., 2017; Srivastava et al.,
2019; Zhang et al., 2019), indicating that other posttranslational
mechanisms are in place to control BOK activity and/or to
sequester it away from mitochondria.
Whether loss of BOK protects cells from specific apoptotic
stresses cannot be generalized and may be highly specific on
the cell type or the nature of the apoptotic stress. Ke et al.
(2012) showed that hematopoietic cells derived from Bok−/−
mice are normally sensitive to dexamethasone, etoposide, FasL,
or ABT-737–induced apoptosis. Likewise, various cell types,
including MEF, were shown to respond normally to etoposide
or staurosporine in the absence of BOK (Echeverry et al., 2013;
Carpio et al., 2015; Fernandez-Marrero et al., 2016). On the
other hand, however, Einsele-Scholz et al. (2016) reported that
knocking down BOK leads to decreased drug-induced (taxol,
cisplatin, camptothecin) cell death of ovarian carcinoma cells,
OVCAR-3, OVCAR-4, and OVCAR-8. This seeming discrepancy
in the involvement of BOK in response to DNA damaging agents
may be explained by cell-intrinsic differences (e.g., amount of
endogenous BOK, cancer cells vs. normal cells) and requires
further investigation. However, what seems to be emerging is
that BOK has important functions at the ER in response to ER
stress (Echeverry et al., 2013; Carpio et al., 2015; Moravcikova
et al., 2017). Carpio et al. (2015) described BOK as a promoter
of cell death in SV40-immortalized MEF in response to various
kinds of ER stress. The authors reported that BOK connects
ER stress signaling to the intrinsic apoptotic machinery through
modulating the UPR, in particular the PERK > ATF4 arm along
with CHOP, which induces the BH3-only protein BIM (Carpio
et al., 2015). Similarly, Kang et al. (2019) found decreased ATF4
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and CHOP expression in erythrocytes derived from Bok−/−
mice compared to WT mice, also suggesting a role for BOK
in modulating the UPR in response to ER stress. In line with
these findings, Rabachini et al. (2018) showed that chemical
[diethylnitrosamine (DEN)]–induced upregulation of CHOP and
BIM, and consequently hepatocellular apoptosis, is reduced
in livers of Bok−/− mice. These studies are supportive of a
proapoptotic role of BOK at the level of the ER and upstream
of mitochondrial apoptotic events (Figure 2). It should also be
mentioned that, in some instances, BOK has been attributed
a protective or apoptosis-unrelated role in response to ER
stress or other stressors and has also been shown to affect
other arms of the UPR, namely, the IRE1α branch (Echeverry
et al., 2013; D’Orsi et al., 2016). Taken together, based on
the current literature, there is increasing evidence to put an
important place of action of BOK at the ER membrane and
it seems that—at the ER—BOK may be best described as a
modulator of UPR signaling in response to ER stress (Carpio
et al., 2016; Fernandez-Marrero et al., 2016). Whereas most of
the previously described effects were derived from cell lines,
the recent study by Ke et al. (2018) provides the up to now
most convincing evidence for a relevant proapoptotic role of
BOK in vivo. One key finding of that study was a more
severe developmental phenotype in Bax−/−Bak−/−Bok−/− full-
body TKO mice compared with Bax−/−Bak−/− DKO controls,
demonstrating overlapping roles of BOK with BAX and BAK
during mouse embryogenesis.
REGULATION OF BOK EXPRESSION
Regulation of BOK expression in health and disease has been
described at transcriptional, epigenetic, and posttranslational
levels, but is overall only incompletely understood (Figure 3).
Within the promoter of human and mouse BOK, a conserved
E2F-binding site has been described (Rodriguez et al., 2006; Luo
et al., 2014). Consequently, Rodriguez et al. (2006) described
BOK to be cell cycle regulated by the transcription factor E2F1,
which upon binding to the promoter activates transcription.
E2F1 plays a crucial role in the control of the cell cycle but is
not only involved in cellular proliferation but also regulates the
expression of BH3-only proteins such as BIM and NOXA and
furthermore mediates p53-dependent apoptosis (Hershko and
Ginsberg, 2004; Zhang et al., 2020). In the model of Rodriguez
et al., starvation followed by serum treatment, which stimulates
quiescent cells to enter S phase, and overexpression of E2F1,
respectively, led to an increase of BOK mRNA in H1299 cells
(Rodriguez et al., 2006). In contrast to the above findings, Ha et al.
(2001) found an increase in BOK mRNA upon serum starvation,
rather than serum stimulation in HC11 mammary epithelial cells
as well as in mouse mammary glands. Yet, the mechanism behind
the observed BOK upregulation in this report has not been
resolved. In all cases, however, the increase in BOK was correlated
with an increase in apoptosis. But, while apoptosis induction
in the mouse mammary gland was described as a physiological
process after weaning, the increased induction of apoptosis
in H1299 cells was observed only in response to an extrinsic
stressor (Ha et al., 2001; Rodriguez et al., 2006). Within the
BOK promoter region, Luo et al. (2014) described the presence
of hypoxia response elements (HREs). Hypoxia-inducible factors
play an important role in adapting the cellular metabolism in
response to cellular stress caused by hypoxia (Vanderhaeghen
et al., 2020) and were shown to bind to HRE in the promoter
region of BOK, leading to an induction of BOK expression
and increase in mitochondrial apoptosis (Soleymanlou et al.,
2005, 2007; Luo et al., 2014). Furthermore, the expression of
BOK, as well as of BAX, has been reported to be controlled
by Wnt signaling in intestinal cancer (Zeilstra et al., 2011).
Dysregulated Wnt signaling, which is frequently observed in
sporadic CRC patients, was correlated with an increase in BOK
and BAX mRNAs and accordingly with increased apoptotic
activity (Zeilstra et al., 2011).
In a variety of human cancers, BOK is frequently found to
be downregulated. Often, this downregulation can be associated
with the deletion of the genomic region containing the BOK
locus (Beroukhim et al., 2010). Moreover, epigenetic silencing
by promoter methylation has been described in non–small
cell lung carcinoma (NSCLC) (Moravcikova et al., 2017). In
colorectal carcinoma tissue, in which BOK protein was also
found to be decreased compared to matched healthy tissue,
promoter hypomethylation rather than hypermethylation has
been observed, thus excluding epigenetic downregulation in CRC
(Carberry et al., 2018; Srivastava et al., 2019). Hence, so far, only
little is known about the epigenetic regulation of the BOK gene.
At the level of mRNA stability and translation, BOK was
found to be downregulated by binding of the miRNA miR-296-
5p to its 3’ UTR in breast cancer cells (Onyeagucha et al., 2017).
Furthermore, destabilizing (AU/U)–rich elements [one AU-rich
element (ARE) site in mouse Bok, two U-rich element (URE)
sites in human BOK] were recently described in the 3’ UTR
of BOK (Fernandez-Marrero et al., 2018). In that study, the
authors identified tripartite motif containing 28 (TRIM28), a
large pleiotropic protein that is known for its many roles at the
genomic level in the nucleus (Czerwinska et al., 2017), as a novel
URE-binding protein triggering the degradation of human BOK
mRNA (Figure 3; Fernandez-Marrero et al., 2018).
At the protein level, little is known about BOK activation or
how possible changes in subcellular localization are regulated.
BOK protein stability is regulated by ubiquitination and
proteasomal degradation and may be cell type specific (Schulman
et al., 2013, 2016; Llambi et al., 2016; Moravcikova et al., 2017;
Sopha et al., 2017). Schulman et al. (2013, 2016) showed that
major portions of cellular BOK are constitutively bound to
IP3R and protected from degradation, whereas newly synthesized
BOK is quickly degraded by the ubiquitin–proteasome pathway.
More specifically, BOK is rapidly turned over by the ERAD
components AMFR/gp78, by which BOK is ubiquitylated, and
VCP/p97, a complex that processes ubiquitylated BOK further
for proteasomal degradation. Upon inhibition of ERAD, or of
proteasome activity, BOK protein gets stabilized and induces
MOMP (Llambi et al., 2016). Whether and how BOK translocates
from the ER to mitochondria are not known. One possibility is
that BOK is already present at mitochondria–ER contact sites,
such as mitochondria-associated membranes (MAM), which
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again needs further investigation (Figure 2; Giacomello and
Pellegrini, 2016).
ROLE OF BOK IN PATHOPHYSIOLOGY
AND CANCER
There is increasing evidence pointing toward BOK as a
prognostic or predictive marker in cancer. Interestingly, the
genomic region containing BOK was identified to be relatively
frequently deleted across many types of human cancers
(Beroukhim et al., 2010). Given the evidence for a proapoptotic
role of BOK, this finding could hint toward a tumor suppressor–
like activity of BOK. However, the peak region of the genomic
deletion in question contains 18 other genes (Beroukhim
et al., 2010) and hard evidence that BOK is indeed a tumor
suppressor is currently missing. Nevertheless, the finding that
BOK is one of the most frequently deleted genes among
the proapoptotic family members was unexpected and merits
further investigation. Besides loss of BOK through somatic copy-
number variations, epigenetic repression of BOK expression
was proposed from studies in NSCLC cell lines (Moravcikova
et al., 2017). Here, analysis of primary NSCLC patient samples
revealed that BOK protein levels are reduced in NSCLC tumors
compared with matched healthy lung tissue. Importantly, in
poorly differentiated tumors, as well as in tumors of patients
with lymph node infiltrations and metastases, BOK protein
was even further decreased. For those patients, a weak positive
correlation between BOK protein and overall survival was
identified. Hence, these data do support a tumor-suppressing
action of BOK and suggest that BOK protein levels may be
useful as a prognostic marker in late-stage NCSLC patients
(Moravcikova et al., 2017). Of note, that study also provided
evidence that BOK does not directly induce apoptosis or affect
apoptotic responses toward chemotherapeutic drugs, but rather
that high BOK levels antagonize transforming growth factor β–
induced epithelial-to-mesenchymal transition and may thus slow
down malignant transformation (metastasization) of NSCLC.
Mechanistically, it was suggested that this function is mediated
via the modulation of the PERK > ATF4 arm of the UPR,
a function of BOK first described by Carpio and colleagues
(Carpio et al., 2015; Moravcikova et al., 2017). In line with
this, Kang et al. (2019) described BOK to be important for
erythropoiesis in the context of Nup98-HoxD13 (NHD13)–
driven myelodysplastic syndrome. In this study, the induction
of ATF4 and CHOP was significantly reduced in erythrocytes
derived from Bok−/− mice compared to WT mice. While
erythropoiesis in Bok−/− mice was not affected compared to WT
mice, NHD13 transgenic mice showed reduced BFU-E (blast-
forming units–erythroid) colonies and a progressive anemia
when BOK was lost (Kang et al., 2019). It was concluded
that BOK contributes to erythropoiesis under stress conditions,
probably via modulation of the ATF4 pathway (Table 1;
Kang et al., 2019).
BOK mRNA stability is negatively regulated by the presence
of one ARE in the mouse and two URE in the human 3’ UTR
(Fernandez-Marrero et al., 2018). TRIM28 was identified as one
of the factors binding to the UREs in human BOK mRNA,
leading to its degradation. TRIM28 is overexpressed in various
cancers in which it is associated with poor prognosis (Czerwinska
et al., 2017). Of note, TRIM28 and BOK levels were found to be
negatively correlated in selected cancers such as hepatocellular
carcinoma and kidney cancer. In those cancers, high BOK and
low TRIM28 mRNA levels correlated with increased survival,
and low BOK and high TRIM28 levels with decreased survival
(Fernandez-Marrero et al., 2018). Translational silencing of BOK
mRNA by miRNA miR-296-5p was reported by Onyeagucha et al.
(2017) in human breast cancer cell lines. This study also describes
an miR-296-5p–mediated regulatory feedback loop between
MCL-1 and BOK levels that determines whether the breast cancer
cells die by apoptosis or survive. Like in NSCLC, BOK protein
levels were again found to be significantly lower in tumor tissue
compared to matched normal tissue, and higher BOK expression
positively correlated with overall as well as with relapse-free
survival of breast cancer patients (Onyeagucha et al., 2017).
Besides NSCLC and breast cancer, BOK has been shown to
be downregulated in CRC and to be of potential prognostic and
predictive value, respectively (Carberry et al., 2018; Srivastava
et al., 2019). Srivastava et al. (2019) reported increased resistance
of BOK-deficient CRC cells and MEFs toward 5-FU and showed
that CRC cells lose BOK expression when becoming resistant
to 5-FU. Mechanistically, that study showed that BOK directly
interacts and thereby activates the enzymatic activity of UMPS
and provided the first connection of BOK to uridine and
nucleotide metabolism (Srivastava et al., 2019). UMPS is a central
enzyme in both the conversion of 5-FU into its active metabolites,
as well as in the de novo synthesis of UMP and hence pyrimidine
nucleotides. A consequence of the latter was that BOK-deficient
cells show a proliferation defect that is likely caused by an increase
in p53 activity at steady state. Importantly, this growth defect
of BOK−/− cells could be rescued by reintroduction of WT
BOK, but not of a BOK mutant that fails to interact with UMPS
(Srivastava et al., 2019). Overall, this study identified BOK as a
double-edged sword in CRC. On the one hand, 5-FU–treated
CRC cells acquire a selective advantage by losing BOK; on the
other hand, this advantage costs them proliferative potential. The
latter may put selective pressure on the BOK-deficient cells to
lose cell cycle inhibitors and/or p53 activity, eventually resulting
in a faster-growing and likely more aggressive phenotype. BOK
is therefore suggested to serve as a predictive marker in CRC,
and the authors proposed to explore the potential of BOK-
mimetic compounds to sensitize resistant CRC to 5-FU treatment
(Srivastava et al., 2019). The observation by Carberry et al.
(2018) that high BOK levels in CRC surprisingly correlate with
reduced overall survival may be dependent on the time of biopsy
(tumor stage) and could possibly be explained by the decreased
proliferation of BOK-deficient, yet still p53 proficient, tumors.
The role of BOK in affecting cellular proliferation, cancer
development, and progression was also reported in a chemical-
induced hepatocellular carcinoma model in the mouse
(Rabachini et al., 2018). The carcinogen DEN triggers acute
hepatic injury and a subsequent inflammatory response that is
followed by compensatory hepatocyte proliferation. Regarding
the acute phase, livers from Bok−/− mice were shown to
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be protected from hepatocellular apoptosis induced by DEN
through induction of CHOP, BIM, and PUMA (Rabachini et al.,
2018). These data provided evidence for a proapoptotic role
of BOK in a pathophysiologically relevant setting, whereas it
suggested at the same time an “indirect” killing mechanism,
with BOK inducing cell death upstream of CHOP and BH3-only
proteins, and thus likely upstream of MOMP. Because of the
protection during the acute phase, Bok−/− mice developed
fewer tumors at the endpoint of 9 months. Of note, the tumors
in Bok−/− mice were also smaller and showed a reduced
proliferative index. Furthermore, BOK-deficient HCC cells and
MEF proliferated slower compared to BOK proficient cells,
which is in line with the growth defect reported in the study of
Srivastava et al. (2019) and others (Ray et al., 2010; Moravcikova
et al., 2017; Zhang et al., 2019).
Besides cancer, BOK expression and regulation have been
connected with preeclampsia, a placental disease that may
occur during pregnancies and that is characterized by a
reduced oxygenation of trophoblast cells, increased trophoblast
cell death, and trophoblast hyperproliferation (Chaiworapongsa
et al., 2014). The Caniggia laboratory reported physiological
BOK expression in proliferating trophoblast cells that is
further increased in preeclampsia, where it contributes to the
hyperproliferative state of the trophoblasts (Ray et al., 2010).
Of note, in this context, it seems that nuclear localized BOK is
important for cellular proliferation of trophoblast cells during
placental development, while cytoplasmic BOK induces cell
death (Ray et al., 2010). Moreover, in patients suffering from
preeclampsia, a splice variant of BOK, BOK-P, was described
(Soleymanlou et al., 2005; Ray et al., 2010). BOK-P results from
skipping exon 2 (Soleymanlou et al., 2005), which contains the
first of the two existing ATG start codons within the human
BOK gene (a second start codon is localized within human,
but not mouse, exon 3). The resulting BOK isoform lacks the
BH4 and parts of the BH3 domain, as well as parts of the 5’
UTR (Soleymanlou et al., 2005). Apart from cellular proliferation
(Ray et al., 2010) and apoptosis induction (Soleymanlou et al.,
2005), several observations point toward an autophagy regulating
role of BOK in preeclampsia (Kalkat et al., 2013; Melland-Smith
et al., 2015; Ausman et al., 2018). In this setting, upregulation
of BOK due to hypoxic conditions (Kalkat et al., 2013) or due
to ceramide accumulation within the mitochondria (Melland-
Smith et al., 2015; Ausman et al., 2018) leads to an increase in
autophagic flux (Kalkat et al., 2013; Melland-Smith et al., 2015;
Ausman et al., 2018). The involvement of BOK in autophagy
regulation can be explained by the observation that BOK
disrupts the interaction between MCL-1 and Beclin-1, which
ultimately leads to the induction of autophagy (Kalkat et al.,
2013). Beclin-1 has been described to interact with different
antiapoptotic members of the BCL-2 family of proteins via its
BH3 domain, namely, with MCL-1, BCL-2, and BCL-XL (Marino
et al., 2014). These interactions can be disrupted by several
BH3-only proteins of the Bcl-2 family–like NOXA and PUMA
(Marino et al., 2014) and supposedly also by BOK (Kalkat et al.,
2013), leading to an increase in freely available Beclin-1 and
subsequent autophagy induction (Kalkat et al., 2013; Marino
et al., 2014). However, the model that the interaction of different
BCL-2 family members with Beclin-1 is sufficient to regulate
autophagy under physiological conditions has been challenged
(Lindqvist et al., 2014). Lindqvist et al. (2014) proposed that
endogenous levels of the BCL-2 family proteins are not able
to directly influence autophagy, since the binding of Beclin-1
with the BH3 domain of different BCL-2 family members is
rather weak and thus insufficient to lead to the sequestration of
Beclin-1. They concluded that the impact of the BCL-2 family
on autophagy is indirect through BAX and BAK inhibition by
prosurvival BCL-2 family members rather than direct through
effects on Beclin-1 (Lindqvist et al., 2014). In their model, the
inhibition of BAX/BAK and the resulting inhibition of apoptosis
lead to the activation of autophagy by a yet unknown mechanism
(Lindqvist et al., 2014). Nevertheless, given that several other
groups ascribe a role of various members of the BCL-2 family not
only to apoptosis but also to autophagy induction and repression,
respectively, it seems likely that BOK may likewise play a role in
the regulation of autophagy initiation. Whether this regulation is
important under physiological or only under pathophysiological
conditions needs further investigation.
CONCLUSION
Over the last years, various functions have been described for
BOK. However, its main function (or functions) remains elusive,
and there are still many riddles to be answered. What exactly is
its role in apoptosis? Does the function of BOK depend on the
intracellular organelle it localizes to, i.e., does it exert different
functions at the ER membrane, mitochondrion, or in the nucleus,
respectively? What is its role in cancer progression, and why do
many types of human cancer lose BOK expression? Does it act
as tumor suppressor and, if so, in which cancer subtypes and by
what mechanism? Currently, a lot of discordance on BOK and its
function can be found in the literature, which makes it difficult
to fully grasp the key roles of this protein. In part, this problem
may be explained by different cellular systems, mouse models,
and different disease settings that have been used by different
groups. It, however, also indicates that—more than 20 years after
its discovery—there remain lots of open questions and work to be
done to understand this fascinating and multifaceted member of
the BCL-2 family.
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